Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors - Asia Hong Kong PI (EN)
{{banner.link_text}}
For investors in Hong Kong

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE00BFRSYJ83

NAV
USD 32.42
As of 2024/12/20

1-Day Change
USD 0.07 (0.22%)
 As of 2024/12/20

Morningstar Rating

As of 2024/11/30

Morningstar Medalist Rating ™

Morningstar Analyst Rating
As of 2024/10/07

Key investment risks:

  • The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
  • Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related

More

  • risks. In extreme market conditions, you may lose your entire investment.
  • The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
  • The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
  • Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Less

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care

Portfolio Management

Andy Acker, CFA
Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA
Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative Performance (%)
As of 2024/11/30
H2 USD (Net) MSCI World Health Care NR Sector Equity Healthcare - OE
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2000/03/31
H2 USD (Net) -0.68 -6.29 4.35 11.75 20.19 23.89 61.04 640.46
MSCI World Health Care NR -0.87 -8.47 1.61 7.68 12.45 13.46 48.62 506.16
Sector Equity Healthcare - OE 0.18 -5.28 2.56 4.83 10.85 -3.34 23.39 326.88
The H2 USD share class was launched on 2013/10/31. Performance prior to that date is past performance based on the I2 USD share class of the same fund which has a different current ongoing charge included of 1.56.
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
Calendar Year Returns (%)
As of 2024/09/30
H2 USD (Net) MSCI World Health Care NR Sector Equity Healthcare - OE
2023 2022 2021 2020 2019
H2 USD (Net) 7.04 -2.89 6.35 25.23 28.95
MSCI World Health Care NR 3.76 -5.41 19.80 13.52 23.24
Sector Equity Healthcare - OE 2.67 -13.91 7.12 20.53 21.80
The H2 USD share class was launched on 2013/10/31. Performance prior to that date is past performance based on the I2 USD share class of the same fund which has a different current ongoing charge included of 1.56.
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.

Recommended holding period 5 Years

Example Investment: USD 10,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs1,430 USD1,490 USD
Average return each year-85.67%-31.62%
UnfavourableWhat you might get back after costs8,150 USD9,970 USD
Average return each year-18.49%-0.06%
ModerateWhat you might get back after costs11,330 USD16,880 USD
Average return each year13.31%11.04%
FavourableWhat you might get back after costs14,590 USD22,120 USD
Average return each year45.85%17.21%
There is currently insufficient data to provide a useful indication of past performance to investors.
Fee Information
Initial Charge 0.00%
Annual Charge 0.80%
Ongoing Charge
(As of 2023/12/31) 		0.87%
The ongoing charge is calculated using the Packaged Retail Investment Product (PRIIPs) methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.
Please refer to the offering documents for more details on the fees and expenses.

Portfolio

Top Holdings (As of 2024/11/30)
% of Fund
Eli Lilly & Co 8.51
UnitedHealth Group Inc 7.36
Novo Nordisk A/S 4.29
AstraZeneca PLC 3.50
Amgen Inc 3.00
Johnson & Johnson 2.96
Abbott Laboratories 2.67
Boston Scientific Corp 2.65
Vertex Pharmaceuticals Inc 2.53
Sanofi SA 2.52
TOTAL 39.99
Portfolio holdings are subject to change without notice. 
Sector Allocation % of Fund % of Index % of Fund % of Index As of 2024/11/30
Regional Allocation % of Fund % of Index % of Fund % of Index As of November 30, 2024

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Despite political headwinds, healthcare stocks stay anchored to innovation
4 Dec 2024
Features & Outlooks

Despite political headwinds, healthcare stocks stay anchored to innovation

Andy Acker and Dan Lyons say healthcare investors should expect volatility in 2025 – but also plenty of opportunities for long-term growth.

8 min read

Healthcare stocks shine in a dimming economy
3 Oct 2024
Timely & Topical

Healthcare stocks shine in a dimming economy

The sector’s traditionally defensive qualities and accelerating innovation could stand out amid a potentially slowing economy.

8 min read

Shaping a Brighter Future: AI’s impact on healthcare
10 Sep 2024
Timely & Topical

Shaping a Brighter Future: AI’s impact on healthcare

Hear how AI and other advances in healthcare are transforming patient outcomes and leading to new investment opportunities.

7 min read

Choose region

Country

Language

What type of investor are you?